<DOC>
	<DOCNO>NCT02495857</DOCNO>
	<brief_summary>The study prospective , multi-center , randomize , three-arm , parallel group , clinical study evaluate superiority 3 weekly intra-articular ( IA ) dose 2 mL Investigational hyaluronate compare placebo injected target knee treatment pain subject Osteoarthritis ( OA ) .The safety effectiveness investigational product also compare Euflexxa .</brief_summary>
	<brief_title>A Study Hyaluronate Injectable Viscosupplement Treatment Osteoarthritis Knee</brief_title>
	<detailed_description>The primary objective evaluate safety effectiveness 3 weekly IA dose 2 mL hyaluronate viscosupplement compare placebo injected target knee treatment pain subject OA As secondary objective , study evaluate safety effectiveness 3 weekly IA dose 2 mL Viscosupplement compare Euflexxa inject target knee treatment pain subject OA . In addition , assess effect Viscosupplement pain , stiffness , physical function target knee , well functional health general well-being</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<mesh_term>Hyaluronic Acid</mesh_term>
	<mesh_term>Viscosupplements</mesh_term>
	<criteria>Chronic OA target knee confirm American College Rheumatology Criteria Pain due OA target knee present least 6 month , moderate severe pain score &gt; 50 mm record 100 mm Visual Analogue Scale ( VAS ) follow 50foot walk Subject agree discontinue pain medication least 7 day prior start study A bilateral standing anteroposterior xray confirm Grade 2 3 OA target knee Body mass index â‰¤40kg/m2 Able willing use acetaminophen analgesic ( rescue ) study medication follow condition : acetaminophen dose exceed 4 gram ( 4000mg ) /day subject know chronic liver disease , maximum dose acetaminophen exceed 2 gram ( 2000 mg ) /day subject must able willing discontinue acetaminophen least 24 hour prior studyspecific visit Ability perform procedure require pain index evaluation ( unassisted walk distance 50 foot flat surface go stair ) Agrees use highly effective contraception Able willing complete effectiveness safety questionnaires able read understand study instruction Any major injury target knee within 12 month prior Screening Enrollment Visit Any surgery target knee within 12 month prior Screening Enrollment Visit , Articular procedures transplant ligament reconstruction target knee within 12 month prior Screening Enrollment Visit Inflammatory arthropathy rheumatoid arthritis , lupus arthropathy , psoriatic arthritis Gout calcium pyrophosphate disease target knee flare within 6 month prior Screening Enrollment Visit Xray finding acute fracture , severe loss bone density , avascular necrosis , and/or severe bone joint deformity target knee Osteonecrosis either knee Clinical sign symptom active knee infection crystal disease target knee Fibromyalgia , pes anserine bursitis , lumbar radiculopathy , and/or neurogenic vascular claudication Significant anterior knee pain due diagnose isolated patellafemoral syndrome chondromalacia target knee Significant target knee joint , infection skin disorder infection within 6 month prior study enrollment Symptomatic OA hip , spine , ankle , interfere evaluation target knee Known hypersensitivity acetaminophen study medication component Women childbearing potential pregnant , nursing , plan become pregnant History recurrent severe allergic immune mediate reaction immune disorder Vascular insufficiency lower limbs peripheral neuropathy severe enough interfere study evaluation Intraarterial corticosteroid ( investigational market ) joint within 3 month Screening Enrollment Visit Current treatment , treatment within 2 year prior Screening Enrollment Visit , malignancy Active liver disease base liver profile aspartate aminotransferase , alanine aminotransferase , conjugate bilirubin &gt; 2 time upper limit normal Renal insufficiency base serum creatinine &gt; 2.0mg/dL Any intercurrent chronic disease condition might interfere completion study Current alcoholism and/or know current addiction pain medication Participation experimental device study within 6 month prior Screening Enrollment Visit , participation experimental drug study within 1 month prior Screening Enrollment Visit .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>